Welcome to our dedicated page for Sage Therapeutic news (Ticker: SAGE), a resource for investors and traders seeking the latest updates and insights on Sage Therapeutic stock.
Sage Therapeutics reports developments tied to its brain-health biopharmaceutical business, including commercialization updates for ZURZUVAE® (zuranolone), an FDA-approved oral treatment indicated for adults with postpartum depression. Company news has also covered collaboration revenue, shipment trends, disease-awareness initiatives, and financial results connected to the postpartum depression market.
Recurring updates also address Sage’s pipeline and corporate matters, including SAGE-319, an extrasynaptic-preferring GABAA receptor positive allosteric modulator being investigated for behavioral symptoms associated with certain neurodevelopmental disorders, early discovery work within its NMDA NAMs platform, governance changes, strategic-review activity, and public-company status changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.